FB 04 - Universitätsmedizin
Johannes Gutenberg-Universität Mainz
- 06131/17-9704 oder 9799 (Sekretariat)
- 06131/17-9669
Bernow, N; Yakushev, I; Landvogt, C et al.
Dopamine D2/D3 receptor availability and venturesomenessPSYCHIATRY RESEARCH-NEUROIMAGING. Bd. 193. H. 2. 2011 S. 80-84
Reiner, I; Spangler, G
Dopamine D4 Receptor Exon III Polymorphism, Adverse Life Events and Personality Traits in a Nonclinical German Adult SampleNEUROPSYCHOBIOLOGY. Bd. 63. H. 1. 2011 S. 52-58
Breitling, LP; Muller, H; Illig, T et al.
Dopamine-related genes and spontaneous smoking cessation in ever-heavy smokersPHARMACOGENOMICS. Bd. 12. H. 8. 2011 S. 1099-1106
Fisch, M; Stein, R
Doppelter Ureter, Ektopie und UreterozeleStein R, Beetz R, Thüroff JW (Hrsg). Kinderurologie in Klinik und Praxis. 3. Aufl. Stuttgart: Thieme 2011
Schmitz, T; Blaickner, M; Ziegner, M et al.
Dose determination using alanine detectors in a mixed neutron and gamma field for boron neutron capture therapy of liver malignanciesACTA ONCOLOGICA. Bd. 50. H. 6. 2011 S. 817-822
Zang, S; Ponto, KA; Pitz, S et al.
Dose of intravenous steroids and therapy outcome in Graves' orbitopathyJOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. Bd. 34. H. 11. 2011 S. 876-880
Boeker, K; Mauss, S; Hueppe, D et al.
Dose Reduction of Peginterferon Alfa-2a (PEG) in Combination With Ribavirin (RBV) in Chronic Hepatitis C (CHC) Patients: Impact on Virological Response Under Real Life ConditionsGASTROENTEROLOGY. Bd. 140. H. 5. 2011 S. S948-S948
Boeker, K; Mauss, S; Hueppe, D et al.
DOSE REDUCTION OF PEGINTERFERON ALFA-2A (PEG) IN COMBINATION WITH RIBAVIRIN (RBV) IN CHRONIC HEPATITIS C (CHC) PATIENTS: IMPACT ON VIROLOGICAL RESPONSE UNDER REAL LIFE CONDITIONSJOURNAL OF HEPATOLOGY. Bd. 54. 2011 S. S162-S162
Lasarzik, I; Noppens, RR; Wolf, T et al.
Dose-Dependent Influence of Sevoflurane Anesthesia on Neuronal Survival and Cognitive Outcome After Transient Forebrain Ischemia in Sprague-Dawley RatsNEUROCRITICAL CARE. Bd. 15. H. 3. 2011 S. 577-584
Urbanik, T; Kohler, BC; Boger, RJ et al.
Down-regulation of CYLD as a trigger for NF-kappa B activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cellsINTERNATIONAL JOURNAL OF ONCOLOGY. Bd. 38. H. 1. 2011 S. 121-131